Chris Lau, Kapitall: It is generally thought that when a stock is hot and continues to rise, its stretched valuation makes it inherently riskier to hold. When a stock filter like this one is run, the companies listed on results have an average forward P/E of a lofty 25, and a 1-year average return of 88%. Together, the companies represent a diversification of 68%. From the companies listed in the table below, three of the companies (in bold) could hold more upside due to their progressive price move over the last few months. (More from Kapitall: Insiders Are Buying These 3 Undervalued U.S. Stocks) Analysis In the technology sector, Rackspace Hosting (RAX) is notably on a downtrend. The company is down 16% over a one year period after peaking at $80 at the beginning of 2013. IBM ( IBM) became a bigger rival after the company acquired SoftLayer, a web hosting and cloud infrastructure firm. Rackspace shares are down because the company reported weak first quarter results last month. The company earned $0.20 per share on revenue of $362.2 million. Cash flow was -$1 million. Analysts quickly downgraded their ratings on the company. As cloud offerings become more important for Microsoft and Google, competitive pressures will mount for Rackspace. In the coffee market, Green Mountain Coffee Roasters (GMCR) is up 89.6% in 2013. The consumer goods company sealed a 5-year deal with Starbucks (SBUX) to add more products made by Green Mountain Coffee. This will triple the number of Starbucks products and raise the product exposure of the Keurig brand at Starbucks locations Green Mountain is in a sweet spot right now with strong revenue growth and higher profits. The company expects to earn $3.05 – $3.15 per share this year on a sales growth of 11% to 14%.
In the pharmaceutical space, Vertex Pharmaceuticals (VRTX) rose nearly 60% on April 19 2013 after reporting Phase 2 study results. The company said that data from its study for treatment for cystic fibrosis was statistically significant. Lung function improved in subjects with cystic fibrosis who were treated with the Vertex Pharmaceuticals drug, VX-661. Six abstracts from the program were presented at the Cystic Fibrosis Society Conference in Portugal on June 12 to 15, 2013.Written by Chris Lau, Kapitall Contributor